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ABSTRACT
Objective: To estimate the incidence and prevalence
of polycystic ovary syndrome (PCOS) in UK primary
care and investigate prescribing patterns before and
after a PCOS diagnosis.
Design: Retrospective cohort study.
Setting: UK primary care (2004–2014).
Participants: Women aged 15–45 years.
Primary and secondary outcome measures: The
incidence and prevalence of diagnosed PCOS and
probable PCOS (ie, those without a confirmed
diagnosis but with at least 2 PCOS features recorded
within 3 years). Among women with diagnosed or
probable PCOS, the prevalence of prescribing of drugs
typically used to treat PCOS was calculated prior to
and in the 24 months after the diagnosis of PCOS.
Results: We identified 7233 women with PCOS
diagnoses and 7057 women with records suggestive of
probable PCOS, corresponding to incidence rates of
0.93 and 0.91 per 1000 person-years at risk (PYAR)
and an overall rate of 1.84 per 1000 PYAR. Women
aged 20–24 years and women living in deprived areas
had the highest incidence of PCOS. The prevalence of
PCOS in 2014 was ∼2%. The proportion of women
with a prescription in the 24 months after their PCOS
index date varied by drug type: 10.2% metformin,
15.2% combined oral contraceptives, 18.8% acne-
related treatments, 1.93% clomiphene, 1.0%
spironolactone, 0.28% cyproterone and 3.11%
eflornithine. Acne-related treatments were more
commonly used to treat probable (28.3%) than
diagnosed (12.3%) cases, while metformin was
prescribed much more commonly in diagnosed cases.
Conclusions: In conclusion, compared to rates
estimated in community samples, the incidence and
prevalence of women presenting in primary care with
PCOS diagnoses and features are low, indicating that
PCOS is an under-recognised condition. Although
considerable variation is observed in treatments
prescribed to women with PCOS, the treatments
initiated following a confirmed diagnosis generally
reflect the long-term prognostic concerns raised in
PCOS consensuses.
BACKGROUND
Polycystic ovary syndrome (PCOS) is asso-
ciated with a wide range of reproductive,
cardiometabolic and dermatological abnor-
malities. One of the most prominent symp-
toms in patients with PCOS is
oligomenorrhea. Consequently, women with
PCOS are highly likely to be infertile and
potentially develop endometrial hyperplasia
due to continuing secretion of oestrogen
without ovulation.1 2 Furthermore, emerging
evidence has suggested that ∼50–70% of
patients with PCOS have insulin resistance
regardless of their body weight or body mass
index.3 Consequently, women with PCOS are
at an elevated risk of developing various
common metabolic disorders compared with
the general population.4 In addition, many
patients with PCOS are observed to have an
elevated androgen level, which leads to hir-
sutism, alopecia and acne.1
While the epidemiology of PCOS in the
community has been well studied,5–8 the pro-
portion of women who present in routine
clinical practice with PCOS features and the
extent to which these women are subse-
quently diagnosed are less clear. Similarly,
Strengths and limitations of this study
▪ The current study is the first to investigate the
incidence and prevalence of polycystic ovary syn-
drome (PCOS) in the primary care setting in the
UK and the longitudinal nature of the database
allowed us to examine trends over a long time
period, which has not been captured by previous
epidemiological studies.
▪ Underdiagnosis was the main concern for the
current study as only data considered relevant at
the time of a consultation are recorded by clini-
cians although we attempted to include women
with two or more features of PCOS as potential
cases.
▪ Our study investigated the prescribing patterns
of PCOS in the UK primary care, which has not
been well explored in previous studies. These
findings reflected the current management of
PCOS in the clinical practices and provide
important indications for general practitioners.
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while a range of treatments have been suggested for the
management of PCOS,9 there is very little information
regarding which of these drugs are actually prescribed
in routine clinical practice. Such ‘real-world evidence’
can help identify priority areas for research, training
and health promotion efforts. The current study sought
to provide such evidence by investigating the recording
of PCOS features and diagnoses in UK general practice
between 2004 and 2014 and the subsequent prescribing
of pharmacological treatments.
METHODS
Data source
The Health Improvement Network (THIN) is one of the
largest primary care data sources in the UK, including
data from over 500 general practices, covering ∼6.2% of
the total population in the UK. Available data include
patient demographics, medical history, test results, drug
prescriptions and social deprivation as measured by
quintiles of the Townsend score.10 Symptoms and diag-
noses are recorded using a hierarchical clinical coding
system (Read codes),11 with additional information
recorded as unstructured text. The information stored
as unstructured text was not available in this study.
Notably, as the data are collected in routine clinical prac-
tice, only information deemed clinically relevant is
entered in a patient’s record.
In our study, data were included from each practice
that met minimum quality criteria, for example, accept-
able computer usage (a time point when a practice is
considered to use their computer system adequately, ie,
at least one medical record, one additional health data
record such as body mass index, laboratory test results
and two therapy records are computerised annually for
a practice) and acceptable mortality reporting (a time
point which the observed death rates for a practice
reach the standard predicted numbers of deaths derived
from National statistics given the practice’s demogra-
phics).12–14
Study population
Women aged 15–45 years, who were permanently regis-
tered for at least 1 year, were included in the study popu-
lation. Women with conditions that can cause similar
symptoms to PCOS were identiﬁed and excluded. These
conditions include prolactinoma, Cushing’s syndrome,
Nelson’s syndrome, adrenal-related disorders (ie,
adrenal tumours, adrenal hyperplasia) and pituitary
disorders.
Case definition
PCOS cases were identiﬁed using two methods. First,
Read codes for ‘polycystic ovary syndrome’ (C165.00),
‘Stein-Leventhal syndrome’ (C164.12) and ‘endoscopic
drilling of ovary’ (7E25300) were used to identify those
women who had been clinically diagnosed as PCOS
cases (diagnosed cases). Women with two or more Read
codes indicative of PCOS features (menstrual/ovarian
dysfunction, clinical and biochemical hyperandrogen-
ism, polycystic ovaries) recorded in a 3-year period were
then selected and we considered these as probable
cases. These women were considered as those who were
likely to meet at least one of the three major deﬁnitions
of PCOS15–18 but who may not have been clinically diag-
nosed as having the condition. The index date for prob-
able cases was considered to be the date the second
PCOS feature was recorded. A full list of the codes used
to deﬁne cases is provided in online supplementary
table SI.
Covariates and prescription indicators
We extracted data on each woman’s year of birth, ethni-
city and deprivation level of the area in which the
woman lived;10 data on prescriptions of interest (ie,
combined oral contraceptives (COCs), progestin oral
contraceptives (POCs), intrauterine devices, clomi-
phene, metformin, spironolactone, gonadotrophins,
cyproterone, ﬂutamide, eﬂornithine, weight control/loss
drugs, lipid regulators and acne-related drugs) were also
included and information on prescribing of these drugs
before and in the 24 months after each PCOS case
index data was extracted.
Statistical analysis
For incidence estimation, the rate was computed as the
total number of new PCOS cases recorded between 2004
and 2014 divided by the total number of person-years of
follow-up. Person-time for the denominator was esti-
mated by summing each woman’s follow-up from the
latest among (1) their 15th birthday, (2) 1 year after
registration, (3) the date at which their practice met
minimum quality criteria and (4) the 1 January 2004, to
the earliest of the date among (1) their ﬁrst incident
diagnosis, (2) their date of death, (3) the date they left
the practice, (4) the date data were last collected from
their practice and (5) the 31 December 2014. All inci-
dence rates were reported per 1000 person-years at risk
(PYAR).
Hierarchical (patients were considered to be nested in
each practice) multivariate Poisson regression models
were used to estimate incidence rate ratios and 95% CIs
comparing the incidence of ﬁrst PCOS diagnoses across
5-year age bands, Townsend score quintiles and calendar
period (ie, 2004–2007, 2008–2011 and 2012–2014).
The period prevalence of the diagnosis of PCOS was
evaluated for the calendar year 2014. The denominator
for the prevalence calculation consisted of any women
with at least 1 year of postregistration follow-up, of which
at least 6 months must have occurred in 2014. The
prevalence of PCOS was also estimated within 5-year age
bands. Secondary analysis was carried out to assess the
sensitivity of the prevalence estimate to the length of the
postregistration period (ie, 1 year, 2 years) and the
minimum period registered within 2014 (ie, 3, 6 and
9 months).
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Among the women with a diagnosis of PCOS, we cal-
culated the number and proportion with a prescription
for one of the drugs of interest at any point prior to
their PCOS index date. Among the women without pre-
scription for each drug of interest prior to the index
date, we then calculated the proportion of women with
a prescription for that drug within 2 years after the
PCOS index date. We used cumulative incidence plots to
describe how the proportion initiating different drugs
increased over the 2 years following the PCOS index
date for the time period 2004–2012.
All analyses were performed using STATA V.13.0 and
were carried out for all PCOS cases and stratiﬁed by case
deﬁnition (diagnosed PCOS vs probable PCOS).
RESULTS
In total, 7233 diagnosed and 7057 probable PCOS
cases were identiﬁed among 2 087 107 female indivi-
duals aged 15–45 years old between 2004 and 2014.
Table 1 describes the number of PCOS features identi-
ﬁed in each group. The incidence rate of diagnosed
PCOS cases was 0.93 per 1000 PYAR (95% CI 0.91 to
0.96), whereas the rate for probable cases was 0.91 per
1000 PYAR (95% CI 0.89 to 0.93). This equated to an
overall combined incidence rate of 1.84 PYAR (95% CI
1.81 to 1.87).
The overall incidence of PCOS increased from 1.67
(95% CI 1.58 to 1.77) per 1000 PYAR in 2004 to 2.00
(95% CI 1.89 to 2.10) per 1000 PYAR in 2010, after
which the rate remained relatively constant at ∼2 per
1000 PYAR (ﬁgure 1). The incidence was the highest for
those in the 20–24 year age group (3.59 per 1000 PYAR,
95% CI 3.47 to 3.70), whereas the 40–44 year age group
had the lowest incidence (0.62 per 1000 PYAR, 95% CI
0.58 to 0.66). The age-speciﬁc trend of PCOS diagnoses
was similar for diagnosed and probable cases. After
adjusting for the effects of year and social deprivation,
signiﬁcant differences still remained in the incidence of
PCOS (table 2). In terms of social deprivation, the inci-
dence of PCOS for individuals who were least deprived
was 1.59 (95% CI 1.53 to 1.65) per 1000 PYAR, whereas
among the most deprived, a rate of 2.23 (95% CI 2.15 to
2.32) per 1000 PYAR was estimated. This difference in
rates remained statistically signiﬁcant after adjusting for
effects of other covariates (ie, age and year) and after
stratifying by case deﬁnition (table 2).
The overall prevalence of PCOS in 2014 was ∼2.27%
(95% CI 2.23% to 2.31%), with a prevalence of 1.34%
and 0.93% in diagnosed and probable cases, respectively.
The age-speciﬁc prevalence peaked in the 30–34 year
age group, and decreased for older age groups.
Prevalence estimates were not sensitive to varying the
postregistration period and the time period registered
within 2014, remaining consistently ∼2%.
The proportion of women using one of the
PCOS-related drugs before or after their index date
varied widely across drugs groups (see table 3). At the
time of their PCOS index date, over 40% of women had
previously been prescribed COC, ∼30% had been pre-
scribed acne-related drugs before diagnosis, >18% had
been prescribed POCs and ∼18% had previously been
prescribed at least one of the other drugs (table 3).
Acne-related drugs, COC and metformin were the most
commonly used drugs in the 24 months after a PCOS
record (table 3). Plots describing the cumulative inci-
dence of women with a prescription for each drug type
over the 24 months following their index date are pro-
vided in online supplementary ﬁgure SI. The plots show
that while all drugs show an initial surge in prescribing
on or just after the PCOS index date, this is greater for
some drugs (eg, metformin, acne-related drugs) than
for others (COCs and POCs).
Prescription results stratiﬁed according to whether
PCOS cases were diagnosed or probable are provided in
online supplementary table SII. These results indicate
that acne-related treatments and POCs were more com-
monly used to treat probable than diagnosed cases,
while COCs, metformin, clomiphene, cyproterone, eﬂor-
nithine and weight loss drugs were prescribed more
commonly in diagnosed than probable cases.
Cumulative incidence plots stratiﬁed according to
whether a case was diagnosed or probable illustrate the
Table 1 Number and proportion of diagnosed and
probable cases with major PCOS features
Features
Diagnosed
cases (n=7233)
Probable cases
(n=7057)
Menstrual
dysfunction
2055 (28.4) 6265 (88.8)
Hyperandrogenism 2836 (39.2) 6221 (88.2)
PCO 199 (2.8) 1636 (23.2)
Two or more
features
597 (8.3) 7057 (100)
Values are represented as n (%).
PCOS, polycystic ovary syndrome.
Figure 1 Time trends in PCOS diagnosis recorded (for
diagnosed, probable and total cases). PCOS, polycystic ovary
syndrome.
Ding T, et al. BMJ Open 2016;6:e012461. doi:10.1136/bmjopen-2016-012461 3
Open Access
group.bmj.com on September 22, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Table 2 Recorded rate of PCOS diagnoses by social and demographical characteristics
Diagnosed PCOS Probable PCOS Overall
Rate per 1000
PYAR (95% CI)
Adjusted* IRR
(95% CI)
p
Value
Rate per 1000
PYAR (95% CI)
Adjusted* IRR
(95% CI)
p
Value
Rate per 1000
PYAR (95% CI)
Adjusted* IRR
(95% CI)
p
Value
Townsend
quintile
<0.001 <0.001 <0.001
1 0.80 (0.76 to 0.84) 1 0.80 (0.76 to 0.84) 1 1.59 (1.53 to 1.65) 1
2 0.90 (0.85 to 0.95) 1.14 (1.06 to 1.23) 0.79 (0.75 to 0.84) 0.99 (0.92 to 1.07) 1.69 (1.62 to 1.75) 1.08 (1.02 to 1.14)
3 0.94 (0.90 to 0.99) 1.12 (1.04 to 1.21) 0.91 (0.86 to 0.96) 1.07 (0.99 to 1.15) 1.85 (1.78 to 1.92) 1.10 (1.05 to 1.16)
4 1.02 (0.97 to 1.07) 1.15 (1.06 to 1.24) 0.97 (0.92 to 1.02) 1.06 (0.98 to 1.15) 1.98 (1.91 to 2.05) 1.11 (1.05 to 1.17)
5 1.07 (1.01 to 1.13) 1.15 (1.05 to 1.25) 1.17 (1.11 to 1.23) 1.21 (1.11 to 1.32) 2.23 (2.15 to 2.32) 1.19 (1.11 to 1.26)
Age (years) <0.001 <0.001 <0.001
15–19 1.20 (1.14 to 1.27) 0.69 (0.64 to 0.74) 0.54 (0.50 to 0.59) 0.29 (0.27 to 0.32) 1.75 (1.67 to 1.83) 0.49 (0.46 to 0.51)
20–24 1.72 (1.64 to 1.80) 1 1.87 (1.79 to 1.96) 1 3.59 (3.47 to 3.70) 1
25–29 1.51 (1.44 to 1.58) 0.86 (0.80 to 0.91) 1.49 (1.42 to 1.56) 0.78 (0.73 to 0.83) 2.98 (2.88 to 3.08) 0.81 (0.78 to 0.85)
30–34 1.03 (0.98 to 1.09) 0.58 (0.54 to 0.62) 0.86 (0.81 to 0.91) 0.46 (0.42 to 0.49) 1.88 (1.81 to 1.96) 0.51 (0.49 to 0.54)
35–39 0.45 (0.42 to 0.49) 0.26 (0.24 to 0.28) 0.55 (0.51 to 0.59) 0.30 (0.27 to 0.32) 0.99 (0.94 to 1.05) 0.27 (0.26 to 0.29)
40–44 0.17 (0.15 to 0.19) 0.10 (0.08 to 0.11) 0.45 (0.42 to 0.48) 0.24 (0.22 to 0.26) 0.62 (0.58 to 0.66) 0.17 (0.16 to 0.18)
Year <0.001 <0.001 <0.001
2004–2007 0.91 (0.87 to 0.94) 1 0.82 (0.79 to 0.86) 1 1.73 (1.68 to 1.78) 1
2008–2011 0.94 (0.91 to 0.98) 1.00 (0.95 to 1.06) 0.95 (0.92 to 0.99) 1.13 (1.07 to 1.19) 1.89 (1.84 to 1.94) 1.06 (1.02 to 1.10)
2012–2014 0.96 (0.92 to 1.01) 0.98 (0.92 to 1.04) 0.98 (0.93 to 1.02) 1.13 (1.07 to 1.20) 1.92 (1.86 to 1.98) 1.04 (1.00 to 1.09)
*IRR from multilevel Poisson distribution accounted for practice-level variability and adjusted for other variables considered.
IRR, incidence rate ratio; PCOS, polycystic ovary syndrome; PYAR, person-years at risk.
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differences listed in online supplementary table SII and
further to this show that these differences are typically
established on or immediately after the index date
(ﬁgure 2).
DISCUSSION
Summary
We present data on >14 000 potential PCOS cases
among women aged 15–45 years in primary care across
the UK between 2004 and 2014. 51.2% of these women
had a PCOS diagnosis recorded, while 49.9% did not,
corresponding to incidence rates of 0.93 per 1000 PYAR
(95% CI 0.91 to 0.96) and 0.91 per 1000 PYAR (95% CI
0.89 to 0.93), respectively. The prevalence of PCOS in
2014 was ∼2.27%. There was a considerable variation in
the type of drug prescribed on the day of, or in the
24 months after, a PCOS diagnosis and prescribing dif-
fered between diagnosed and probable cases.
Strengths and limitations
To the best of our knowledge, this study is the ﬁrst to
investigate the diagnosis and management of PCOS in
the primary care setting in the UK. As THIN contains
over 10 million patient records, our study is robust in
terms of sample size. The longitudinal nature of the
database also allowed us to examine trends over a
10-year study period, which has not been captured by
previous epidemiological studies where individuals were
often sampled at a single time point.
As our data were collected in routine clinical practice,
our results reﬂect the true burden of PCOS on the
healthcare system. However, this also means that only
data considered relevant at the time of a consultation
are recorded by clinicians. Consequently, it is unsurpris-
ing that only 8% of diagnosed cases had two or more
PCOS features recorded as, while the initial feature
prompting referral is likely to be noted by the general
practitioner (GP), once a PCOS diagnosis has been
made by a specialist a GP is unlikely to record anything
other than the conﬁrmed diagnosis in the coded
record. The routine nature of data collection also meant
that underdiagnosis was a concern in the current study
and underestimation of PCOS rates was anticipated. We
attempted to address under-reporting by allowing
women with two or more features of PCOS (interfeature
period within 3 years) to count as a PCOS case.
However, the inclusion of probable cases may introduce
case misclassiﬁcation as some probable cases may not be
true PCOS cases. For example, while we considered
women with a raised testosterone level to have hyperan-
drogenism, there are concerns surrounding the accuracy
of testosterone testing.19 On the contrary, it is also pos-
sible that many probable cases are true cases but do not
have a diagnosis recorded in their medical records for
some reason.
Incomplete patient history is a concern as women with
prevalent PCOS diagnoses at the time of registration
with a practice may not be identiﬁed, resulting in the
underestimation of prevalence rates and the overesti-
mation of incidence rates. Additionally, the lack of infor-
mation on ethnicity is also an issue as the trends in
incidence observed over age, deprivation and calendar
year categories may be inﬂuenced by unobserved differ-
ences in ethnicity distributions across these covariates.
As we lack information on the indication for prescrip-
tions, we cannot be certain that prescriptions issued after,
or even on, the date of a PCOS record were prescribed
for the treatment of PCOS. For example, ∼30% of the
PCOS cases prescribed metformin had a prior diagnosis
of type 2 diabetes, the approved indication for this drug.
However, by excluding those ever prescribed metformin
prior to their PCOS diagnosis from our calculations, we
can be relatively conﬁdent that prescriptions for
Table 3 Number and percentage of PCOS women prescribed relevant drugs for PCOS prior to and following the diagnosis
of PCOS
Types of drugs
Before diagnosis of
PCOS, number (%)
After diagnosis of PCOS, number (%)
2004–2007 2008–2011 2012–2014
Combined oral contraceptives 12 349 (40.22) 901 (17.01) 912 (18.87) 459 (17.88)
POC 5806 (18.91) 474 (6.45) 691 (10.22) 272 (7.80)
IUDs 728 (2.37) 43 (0.50) 64 (0.75) 25 (0.52)
Clomiphene 518 (1.69) 210 (2.46) 165 (1.92) 70 (1.43)
Metformin 1278 (4.16) 1212 (14.77) 1102 (13.25) 495 (10.52)
Gonadotrophins 435 (1.42) 29 (0.34) 13 (0.15) 13 (0.26)
Spironolactone 235 (0.77) 109 (1.26) 111 (1.28) 43 (0.87)
Cyproterone 91 (0.30) 28 (0.32) 19 (0.22) 3 (0.06)
Flutamide 6 (0.02) 4 (0.05) 1 (0.01) 0
Eflornithine 550 (1.79) 354 (4.10) 407 (4.81) 172 (3.58)
Weight control/loss drugs 1330 (4.33) 403 (4.84) 364 (4.43) 91 (1.95)
Lipid regulators 194 (0.63) 69 (0.79) 46 (0.53) 8 (0.16)
Acne-related drugs 9000 (29.31) 1182 (19.52) 1234 (20.78) 582 (18.32)
Values are represented as n (%).
COC, combined oral contraceptive; IUD, intrauterine device; PCOS, polycystic ovary syndrome; POC, progestin oral contraceptive.
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metformin issued on the date of a PCOS diagnosis are
likely to be at least partly for the treatment of PCOS. Our
conﬁdence that the drug was prescribed for PCOS then
decreases with increasing time after the PCOS diagnosis
such that we expect the proportion of diagnosed cases
prescribed metformin for PCOS to lie somewhere
between the 8% with a prescription on the date of diag-
nosis and the 20% with a prescription on or in the
24 months after the date of diagnosis.
While we lacked information on prescribing outside
primary care, the responsibility for prescribing treat-
ments which have been initiated by specialists is likely to
be transferred to an individual’s GP a number of
months after diagnosis. The use of a 24-month window
to assess prescribing therefore allowed us to capture ini-
tiation of drugs prescribed in secondary care. This is
reﬂected in the cumulative incidence curves shown in
online supplementary ﬁgure S1 where the drugs that are
commonly initiated outside primary care (eg, spironolac-
tone and clomiphene) are initiated further after the
index date than the drugs typically initiated in primary
care (eg, COCs and acne drugs). However, prescribing
rates may be underestimated if care is not transferred to
the GP within 24 months (eg, for budgetary reasons).
The proportion of women with PCOS who had been
prescribed COCs before their PCOS diagnosis is similar
to that reported by other studies.20 21 The proportion of
women with PCOS who initiated metformin after their
diagnosis in our study (over 10%) is comparable to that
of a Danish study where 11.8% of the women with PCOS
were identiﬁed as having received metformin.21 These
comparisons support the validity of our prescribing data.
Interpretation
The prevalence of recorded PCOS in UK primary care
in 2014 is comparable to that obtained from studies
using databases in the USA (0.56–2.22%).22–24
However, the rates are signiﬁcantly lower than those
from epidemiological surveys in the Europe where sys-
tematic screening was often provided to identify cases
from selected populations.25–28 This gap highlights the
importance for improving public and GPs’ awareness
of PCOS.
The incidence of PCOS increased slightly over the
study period; however, no signiﬁcant changes in yearly
rates were observed. This might reﬂect the increasing
awareness of the syndrome after the establishment of
the Rotterdam and Androgen Excess Society criteria
during the study period. However, it could also be due
to the improvement of the database, that is, the com-
pleteness of medical recordings has improved over time.
It should be noted that the Townsend score represents
the deprivation level of the area in which a woman lives.
Women who lived in more deprived areas had a higher
Figure 2 Plots describing the cumulative incidence of women with a prescription for each drug type over the 24 months
following their index date stratified according to whether the case was diagnosed (dashed line) or probable (solid line). Results
shown for the eight most commonly prescribed drugs. COC, combined oral contraceptive; POC, progestin oral contraceptive.
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incidence of PCOS than those living in the less deprived
areas. A possible explanation is that obesity (a factor
strongly associated with PCOS) is more prevalent among
women living in more deprived areas. Alternatively,
these women may consult their GP more frequently
than those in less deprived areas, for other morbidities
(ie, type 2 diabetes), and therefore have more opportun-
ity for PCOS to be diagnosed and recorded.
The fact that the incidence of probable PCOS cases
was as high as the incidence of diagnosed cases indicates
that there is a large group of women who present in
primary care exhibiting two features of PCOS within a
3-year period but who do not have a subsequent PCOS
diagnosis. While for some of these probable cases a
PCOS diagnosis may not be relevant, it is likely that a
considerable proportion of the women may meet the
diagnostic criteria for PCOS and should therefore be
referred for further assessment. Failure to refer such
women may mean that they are not offered the lifestyle
advice or medications that could reduce their risk of
long-term PCOS-related complications.
Variation was observed in the treatments prescribed to
diagnosed and probable PCOS cases; in particular, a
greater proportion of diagnosed women received met-
formin prescriptions, while a greater proportion of the
probable cases received treatment for the PCOS feature
they presented with. This suggests that the diagnosed
and probable cases are indeed receiving different care
for their condition, with some probable cases not receiv-
ing potentially effective treatments such as metformin.
The wide variation in prescribing patterns may also be
due to the varied nature of clinical presentations of
PCOS not only by individuals and also by age. For
example, young women consulting their GPs are more
likely to ask for drugs to regulate their menses or to
treat acne, whereas more elderly women may initiate
antidiabetic drugs to prevent rapid conversion to
diabetes.
Metformin and oral contraceptives were the two drugs
most commonly initiated in women with diagnosed
PCOS, possibly reﬂecting the major concerns of long-
term metabolic risks of this syndrome stated by the three
PCOS consensuses. However, it is notable that even
among the diagnosed PCOS cases, there is some vari-
ation in treatments prescribed following a diagnosis.
This suggests that there may be a lack of consensus on
the ideal treatment for the condition. This is supported
by a recent survey of European endocrinologists which
found variation in the treatments most commonly pre-
scribed for PCOS.29 Further research into the compara-
tive efﬁcacy and effectiveness of the various PCOS
treatment options may therefore be warranted.
Conclusions
In conclusion, compared to rates estimated in commu-
nity samples, the incidence of women presenting in
primary care with PCOS diagnoses and features is low
compared with most epidemiological surveys. Among
the women who present, only 50% were observed to
have a PCOS diagnosis recorded. Further work is there-
fore needed to inform women and healthcare profes-
sionals about the condition to avoid any worsening of
the disease or rapid conversion into other metabolic dis-
orders considering the relatively low cost of diagnosis
and high cost of care for the associated diseases sug-
gested by Azziz et al.30 There is much potential for these
treatments to prove cost-effective alternatives, which
should be carefully considered by public healthcare pro-
viders, such as the National Health Service in the UK.
Although there is much variation in the treatments
prescribed following a PCOS diagnosis, the widespread
prescribing of oral contraceptives and metformin gener-
ally reﬂects the prognostic concerns raised in PCOS con-
sensuses, aiming to reduce the future metabolic risks of
patients with PCOS or patients who are undergoing
treatment for PCOS and may already have developed
metabolic disorders. Further work is needed to identify
the most effective treatment for the condition.
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